Grayson now wears an external speech processor containing a microphone and he also has an external battery that powers the auditory brain stem implant. Doctor's aren't sure "what" he hears, but we know that he is capable of hearing sound.
Clinton also spoke about global economic issues around inequality, the importance of non-zero-sum, and how the future depends on creative networks of cooperation. He also entertained the audience by wearing some stylish cowboy boots, thus proving that he's a real cowboy.
There's a complimentary webcast coming up titled, "Managing the Data Explosion in Life Sciences Research"Phase IV trial is also known as Post Marketing Surveillance Trial. Phase IV trials involve the safety surveillance (pharmacovigilance) and ongoing technical support of a drug after it receives permission to be sold.Last week, the FDA announced that Ultram and Ultracet may increase the risk of suicide. The drug tramadol is marketed as Ultram and is included in Ultracet. Tramadol is not an opioid, however it possesses weak agonist actions at the μ-opioid receptor, releases serotonin, and inhibits the reuptake of norepinephrine. Some clinicians seem to think that tramadol may be associated with abuse, misuse, and even possibly addiction. The data remains unclear about that.
Are you attending the American Society of Clinical Oncology (ASCO)
annual meeting next month? June 4-8 in Chicago, IL. I was originally planning on being there, but some personal things came up so I had to cancel my trip. 
We currently have drug therapies for a wide variety of conditions. We have ways to treat diabetes and reduce the risk for heart attacks. We have medications for depression and anxiety. We even have medications for schizophrenia and bipolar disorder.
We probably all know someone who has autism. We also probably all know a parent who has a child with autism.The U.S. Food and Drug Administration published two rules today that seek to clarify the methods available to seriously ill patients interested in gaining access to investigational drugs and biologics when they are not eligible to participate in a clinical trial and don’t have other satisfactory treatment options.
To support the effort to help these patients, the agency also is launching a new Web site where patients and their health care professionals can learn about options for investigational drugs. In general, these options include being treated with a drug that has been approved by FDA, being given an investigational drug as part of a clinical trial, or obtaining access to an investigational drug outside of a clinical trial.
The new rule, “Expanded Access to Investigational Drugs for Treatment Use,” makes investigational drugs more widely available to patients by clarifying procedures and standards. The other rule, “Charging for Investigational Drugs Under an Investigational New Drug Application,” clarifies the specific circumstances and the types of costs for which a manufacturer can charge patients for an investigational drug when used as part of a clinical trial or when used outside the scope of a clinical trial.
“With these initiatives, patients will have the information they need to help them decide whether to seek investigational products,” said Margaret A. Hamburg, M.D., Commissioner of Food and Drugs. “For patients seeking expanded access to investigational drugs and biologics, the new rules make the process easier to understand.”
Clinical trials are studies of drugs and biologics that are still in development and have not yet been approved by the FDA. Many patients enroll in clinical trials to gain access to investigational therapies and contribute to finding out how well an investigational therapy works, and how safe it is for patients. Obtaining a drug or biologic under an expanded access program may be an option for some patients who are not able to enroll in clinical trials.
The FDA has allowed expanded access to experimental drugs and biologics since the 1970s. That access has allowed tens of thousands of patients with HIV/AIDS, cancer, and other conditions to receive promising therapies when no approved alternative is available.
“The final rules balance access to promising new therapies against the need to protect patient safety and seek to ensure that expanded access does not discourage participation in clinical trials or otherwise interfere with the drug development process,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “Clinical trials are the most important part of the drug development process in determining whether new drugs are safe and effective, and how to best use them.”
Web site that explains the options for investigational drugs
Final Rules for Expanded Access to Investigational Drugs for Treatment Use and Charging for Investigational Drugs
Dr. Irving Weissman, president-elect of the International Society for Stem Cell Research, told CNN, "There is no such cell. There is nothing called a 'regenocyte.' " "As a stem cell scientist who works in the field of regenerative stem cells, I am disappointed and shocked that somebody would prey on a family that has an untreatable disease with the promise of a therapy that has no scientific or medical basis," Weissman said.So, are you willing to be part of a private research project? I suppose the villains in the James Bond movie had no choice. Did you guess the James Bond movie? Die Another Day. Maybe if we start seeing some high-profile officials (drug lords) visit the Dominican Republic for "medical care," then we'll have a really interesting medical clinic to investigate. Until then, we have to wait to see what type of data can be generated from this interesting practice. To read the CNN story, click here.
Grekos (a cardiologist) has a busy practice in Bonita Springs, Florida, outside Naples, and runs a company that promotes and administers stem cell therapies in Santiago, a noisy, crowded industrial city in the central Dominican Republic.
A year ago, Barbara McKean of Naples, Florida, paid Regenocyte Therapeutic more than $54,000 for stem cell therapy in the Dominican Republic after suffering from chronic lung disease. She said she believes the therapy was worth the expense.
Association of Clinical Researchers and Educators (ACRE) is an organization of medical professionals dedicated to the advancement of patient care through productive collaboration with industry and its counterparts. ACRE seeks to define and promote balanced policies at academic medical centers and within government that will enhance rather than interfere with our highly valued collaboration. In addition, ACRE will identify and train next generation of researchers and educators.To learn more about this group, visit the website: http://www.acreonline.org/
